论文部分内容阅读
目的:比较重组人红细胞生成素联合口服与静脉铁剂治疗维持性血液透析患者贫血的疗效及安全性。方法:将本院2012年6月至2013年6月维持性血液透析后发生贫血的80例患者纳入本研究,均采用重组人红细胞生成素治疗。随机分组,对照组联合口服铁剂治疗,实验组联合静脉铁剂治疗。对比两组在疗效及安全性方面的差异性。结果:实验组患者治疗后血红蛋白(Hb)、红细胞压积(Hct)、血清铁蛋白(SF)、转铁蛋白饱和度(TS)均明显高于对照组,组间差异有统计学意义(P<0.05)。实验组患者治疗期间不良反应发生率明显低于对照组,组间差异有统计学意义(P<0.05)。结论:采用重组人红细胞生成素联合静脉铁剂治疗维持性血液透析患者贫血的临床疗效优于口服铁剂,且不良反应更小,今后可将其推广应用。
OBJECTIVE: To compare the efficacy and safety of recombinant human erythropoietin with oral and intravenous iron in the treatment of anemia in maintenance hemodialysis patients. Methods: Eighty patients with anemia after maintenance hemodialysis from June 2012 to June 2013 in our hospital were enrolled in this study. All patients were treated with recombinant human erythropoietin. The patients in the control group were treated with oral iron and the experimental group were treated with intravenous iron. The differences between the two groups in efficacy and safety were compared. Results: The hemoglobin (Hb), hematocrit (Ht), serum ferritin (SF) and transferrin saturation (TS) of the experimental group were significantly higher than those of the control group after treatment, and the difference was statistically significant (P <0.05). The incidence of adverse reactions in the experimental group was significantly lower than that in the control group during treatment, with significant difference between the two groups (P <0.05). Conclusion: The clinical efficacy of recombinant human erythropoietin combined with intravenous iron in treating hemodialysis patients with hemodialysis is better than that of oral iron with less adverse reactions, so it can be widely used in the future.